Results 131 to 140 of about 4,521 (193)

JAK1-selective inhibitors versus pan-JAK inhibitors: comparative real-world study of drug retention in chronic inflammatory arthritis. [PDF]

Ther Adv Musculoskelet Dis
Leon L, Bermejo PP, Laredo L, Peña Pedrosa JA, Benítez Gimenez MT, Freites D, de Miguel C, Abasolo L.   +7 more
europepmc   +1 more source

JAK Inhibitor and Crohn's Disease. [PDF]

Biomedicines
Xu M, Wang S, Xu S, Gong R.
europepmc   +1 more source

Efficacy and safety of filgotinib in patients with moderately active rheumatoid arthritis and an inadequate response to methotrexate. [PDF]

Rheumatology (Oxford)
Buch MH, Walker D, Edwards CJ, Barry J, Akroyd L, Ekoka Omoruyi EV, Taylor PC.   +6 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Filgotinib

Reactions Weekly
semanticscholar   +9 more sources

Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial.

The Lancet, 2021
BACKGROUND The global prevalence of ulcerative colitis is increasing, and induction and maintenance of remission is a crucial therapeutic goal. We assessed the efficacy and safety of filgotinib, a once-daily, oral Janus kinase 1 preferential inhibitor ...
B. Feagan, S. Danese, E. Loftus, S. Vermeire, S. Schreiber, T. Ritter, R. Fogel, R. Mehta, S. Nijhawan, R. Kempiński, R. Filip, I. Hospodarskyy, U. Seidler, F. Seibold, I. Beales, Hyo Jong Kim, J. McNally, C. Yun, Sally Zhao, Xiaopeng Liu, C. Hsueh, Chantal Tasset, R. Besuyen, Mamoru Watanabe, W. Sandborn, G. Rogler, T. Hibi, L. Peyrin-Biroulet   +27 more
semanticscholar   +1 more source

Filgotinib as rheumatoid arthritis therapy

Drugs of Today, 2021
Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by joint inflammation and progressive disability when inflammation cannot be sufficiently controlled. Despite treatment with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) and biological DMARDs (bDMARDs), up to 30% of RA patients do not reach or fail to ...
A, Becciolini, E, Di Donato, D, Santilli, G, Lucchini, F, Mozzani, M, Riva, A, Ariani   +6 more
openaire   +2 more sources

Filgotinib in rheumatoid arthritis

Expert Review of Clinical Immunology, 2022
Rheumatoid Arthritis (RA) remains a challenge for rheumatologists and patients despite implementation of intensive treat-to-target strategies in shared decision with patients and an increasing availability of drugs. Janus kinase inhibitors (JAKi) are a new generation of oral targeted drugs. Filgotinib preferentially inhibits JAK1 and is the latest JAKi
openaire   +2 more sources

Evaluating filgotinib for the treatment of rheumatoid arthritis

Expert Opinion on Pharmacotherapy, 2021
Despite the availability of an extensive armamentarium, rheumatoid arthritis (RA) remains a therapeutic challenge for rheumatologists. Janus kinase inhibitors (JAKi) are an emerging class of targeted therapies. The number of JAKi has been growing and to date, filgotinib is the latest JAKi to be approved for use in RA.This review focuses on the ...
Christophe Richez, Marie-Elise Truchetet
openaire   +2 more sources

Filgotinib for moderately to severely active ulcerative colitis

Expert Review of Gastroenterology & Hepatology, 2022
Filgotinib is an oral Janus kinase type 1 (JAK1) selective inhibitor with demonstrated efficacy and safety in ulcerative colitis (UC). The aim of this review is to summarize the available evidence on pharmacological characteristics, efficacy, and safety of filgotinib in UC.Pubmed, Scopus, and Embase databases were searched for all relevant studies ...
Alessandro Mannucci, Ferdinando D’Amico, Ahmad El Saadi, Laurent Peyrin-Biroulet, Silvio Danese   +4 more
openaire   +2 more sources